Mar 06th 2013 - Edison Investment Research today published a report on Delcath Systems entitled "Melblez To Face ODAC". In summary, the report says:
Delcath will reach the most important milestone in its 20 plus year history in May this year when the FDA oncology drug advisory committee reviews its Melblez drug/device combination for unresectable ocular melanoma metastatic to the liver. A positive vote by the panel should, in our view, pave the way for approval by 15 June, the PDUFA date, which would be a significant value inflection point.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »